GLANATEC® ophthalmic solution 0.4%
|Target disease||Glaucoma / Ocular hypertension|
|Development stage||Launched in Japan
Filed in Korea
|License out to||Kowa Company, Ltd.|
|Overview||glaucoma & ocular hypertension treatment drug in the clinical studies conducted in the patients with primary open-angle glaucoma and ocular hypertension in Japan. Launched in December 2014 in Japan. Brand name is “GLANATEC® ophthalmic solution 0.4% (nonproprietary name: Ripasudil hydrochloride hydrate)”.
Kowa Co., Ltd. filed for manufacturing and marketing approval in Korea in December 2017.
|2002||Sep.||Licensed all worldwide rights to Kowa Company, Ltd.|
|2006||Jul.||Initiated phase I trial in Japan|
|2007||Oct.||Completed phase I trial in Japan|
|2009||Mar.||Initiated phase II trial in Japan|
|2011||Jan.||Completed phase II trial in Japan|
|Sep.||Initiated phase III trial in Japan|
|2013||Apr.||Completed phase III trial in Japan|
|Oct.||Filed NDA application in Japan|
|2014||Sep.||Acquired Marketing Approval in Japan|
|Dec.||Launched in Japan|
|2017||Dec.||Filed manufacturing and marketing approval in Korea.|
GLANATEC® ophthalmic solution 0.4% Point of Action
Glaucoma is said to develop (*) due to increased ocular pressure, and the glaucoma drug works to decrease ocular pressure. The eye ball is filled with fluid, called aqueous humor to keep ocular pressure. The aqueous humor is produced in the ciliary body and goes through the uveoscleral outflow and Schlemm’s canal outflow before discharged out of the eye. GLANATEC® ophthalmic solution 0.4% promotes outflow of aqueous humor through Schlemm’s canal.
*Glaucoma may develop even if the ocular pressure is in the normal range.
Aqueous Humor Flow
Review of Extension of GLANATEC® ophthalmic solution 0.4% Indication
In February 2014, a phase II clinical study on GLANATEC® ophthalmic solution 0.4% initiated in diabetic retinopathy accompanying diabetic macular edema（Development Code：K-115-R）.
Diabetic retinopathy is a disease in the retina damaged by diabetes, leading to decreased visual acuity and to blindness. The phase II clinical study is under evaluation of the effects of improvement in this disease when instilling GLANATEC® ophthalmic solution 0.4% which was developed as a glaucoma drug having Rho kinase inhibitory action.